{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:40:29Z","timestamp":1743381629601,"version":"3.40.3"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2403,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,2]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Recurrent hepatitis C after liver transplantation is a universal phenomenon. Graft reinfection occurs rapidly; once it is established, allograft cirrhosis and decompensation rapidly ensue in many patients. Treatment with pegylated interferon plus ribavirin is the standard of care among nontransplant patients with hepatitis C; however, the applicability of these therapies in liver transplant patients is severely limited. Before transplantation, many patients are simply too ill to endure the long treatment duration necessary to achieve viral eradication; thus, treatment-related toxicity is a frequent barrier to success. Clinical trials in the pretransplantation population have yielded poor outcomes, with sustained virologic response rates only as high as 25%. Early after transplantation, treatment may be initiated prophylactically, or it may be initiated therapeutically in patients with evidence of recurrent disease. In small studies, prophylactic therapy has been associated with sustained virologic response rates lower than 20%, whereas in therapeutic intervention studies, sustained virologic response rates have ranged from 20% to 37%. In the setting of therapeutic intervention, preliminary indications suggest that rapid and early virologic response may become important clinical tools enabling the early identification of patients likely to respond to treatment. Two important clinical trials, PHOENIX (Pegasys and Copegus Administered After Liver Transplantation for Hepatitis C) in the prophylactic setting and PROTECT (Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy) in the therapeutic setting, are under way and should further advance our understanding of the management of hepatitis C in patients undergoing liver transplantation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/lt.21694","type":"journal-article","created":{"date-parts":[[2009,1,28]],"date-time":"2009-01-28T18:45:29Z","timestamp":1233168329000},"page":"126-135","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Treatment of hepatitis C in liver transplant recipients"],"prefix":"10.1097","volume":"15","author":[{"given":"Fredric D.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Kwo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo E.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-3-20250330","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1016\/S0002-9343(99)00374-5","article-title":"Natural history of hepatitis C.","volume":"107","author":"Seeff","year":"1999","journal-title":"Am J Med"},{"key":"R3-3-20250330","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJM199506013322202","article-title":"Clinical outcomes after transfusionassociated hepatitis C.","volume":"332","author":"Tong","year":"1995","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R4-3-20250330","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1002\/hep.1840360710","article-title":"Hepatocellular carcinoma and hepatitis C in the United States.","volume":"36","author":"ElSerag","year":"2002","journal-title":"Hepatology"},{"issue":"suppl 1","key":"R5-3-20250330","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/hep.1840360705","article-title":"The burden of hepatitis C in the United States.","volume":"36","author":"Kim","year":"2002","journal-title":"Hepatology"},{"issue":"suppl 1","key":"R7-3-20250330","first-page":"238A","article-title":"Decline in the need for liver transplantation for end stage liver disease secondary to hepatitis B in the US. abstract.","volume":"46","author":"Kim","year":"2007","journal-title":"Hepatology"},{"key":"R8-3-20250330","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJM199603283341302","article-title":"Longterm outcome of hepatitis C infection after liver transplantation.","volume":"334","author":"Gane","year":"1996","journal-title":"N Engl J Med"},{"key":"R9-3-20250330","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective followup study of 384 patients.","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"R10-3-20250330","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.510290412","article-title":"Recurrent and new hepatitis C virus infection after liver transplantation.","volume":"29","author":"Everhart","year":"1999","journal-title":"Hepatology"},{"issue":"suppl 3","key":"R11-3-20250330","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/jlts.2003.50268","article-title":"Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.","volume":"9","author":"Wiesner","year":"2003","journal-title":"Liver Transpl"},{"key":"R12-3-20250330","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/jlts.2002.30141","article-title":"Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virusreinfected liver.","volume":"8","author":"Ballardini","year":"2002","journal-title":"Liver Transpl"},{"key":"R13-3-20250330","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/modpathol.3880043","article-title":"Early detection of hepatitis C allograft reinfection after orthotopic liver transplantation: a molecular and histologic study.","volume":"13","author":"Guerrero","year":"2000","journal-title":"Mod Pathol"},{"issue":"suppl 1","key":"R14-3-20250330","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1053\/jlts.2002.35781","article-title":"Natural history of recurrent hepatitis C.","volume":"8","author":"Berenguer","year":"2002","journal-title":"Liver Transpl"},{"key":"R15-3-20250330","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/lt.21123","article-title":"Trends in postliver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States.","volume":"13","author":"Thuluvath","year":"2007","journal-title":"Liver Transpl"},{"key":"R16-3-20250330","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1478-3231.2005.01120.x","article-title":"Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis.","volume":"25","author":"Saab","year":"2005","journal-title":"Liver Int"},{"key":"R17-3-20250330","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/hep.510280334","article-title":"The efficacy of prophylactic interferon alfa2b in preventing recurrent hepatitis C after liver transplantation.","volume":"28","author":"Sheiner","year":"1998","journal-title":"Hepatology"},{"key":"R18-3-20250330","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00007890-199801150-00016","article-title":"Interferonalpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial.","volume":"65","author":"Singh","year":"1998","journal-title":"Transplantation"},{"key":"R19-3-20250330","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.20560","article-title":"Peginterferon alfa2a for hepatitis C after liver transplantation: two randomized, controlled trials.","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"issue":"suppl 1","key":"R20-3-20250330","first-page":"204A","article-title":"Early treatment of recurrent hepatitis C in liver transplant recipients: is the virological and histological response better. abstract?","volume":"122","author":"Nair","year":"2002","journal-title":"Gastroenterology"},{"key":"R21-3-20250330","first-page":"141A","article-title":"Prospective randomized trial on early treatment of HCV infection after liver transplantation in HCVRNA positive patients. abstract.","volume":"9","author":"Mazzaferro","year":"2003","journal-title":"Liver Transpl"},{"issue":"suppl 1","key":"R22-3-20250330","first-page":"632A","article-title":"Interferon alfa2b and ribavirin vs. placebo in early treatment in patients transplanted for hepatitis C endstage liver disease: results of a multicenter randomized trial. abstract.","volume":"122","author":"Reddy","year":"2002","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"R23-3-20250330","first-page":"188A","article-title":"A Randomized controlled trial of prophylactically administered peginterferon alfa2a plus ribavirin vs no prophylaxis following orthotopic liver transplantation (OLT) for hepatitis C: a report of initial safety and tolerability. abstract.","volume":"44","author":"Bzowej","year":"2006","journal-title":"Hepatology"},{"key":"R24-3-20250330","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-6143.2004.00648.x","article-title":"Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis Cinfected patients undergoing liver transplantation.","volume":"5","author":"Shergill","year":"2005","journal-title":"Am J Transplant"},{"key":"R25-3-20250330","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1053\/gast.2003.50095","article-title":"Interferon 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.","volume":"124","author":"Samuel","year":"2003","journal-title":"Gastroenterology"},{"key":"R26-3-20250330","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/lt.20883","article-title":"Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.","volume":"12","author":"Fernandez","year":"2006","journal-title":"Liver Transpl"},{"key":"R27-3-20250330","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/lt.21121","article-title":"Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.","volume":"13","author":"Sharma","year":"2007","journal-title":"Liver Transpl"},{"key":"R28-3-20250330","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1053\/j.gastro.2007.03.041","article-title":"Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.","volume":"132","author":"Carrion","year":"2007","journal-title":"Gastroenterology"},{"key":"R29-3-20250330","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jhep.2005.02.015","article-title":"Combined treatment with pegylated interferon (2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.","volume":"43","author":"Castells","year":"2005","journal-title":"J Hepatol"},{"key":"R30-3-20250330","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.TP.0000100481.14514.BB","article-title":"Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon 2b and ribavirin: an openlabel series.","volume":"77","author":"RodriguezLuna","year":"2004","journal-title":"Transplantation"},{"key":"R31-3-20250330","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1399-0012.2003.00145.x","article-title":"Pegylated interferon 2b plus ribavirin in the treatment of postliver transplant recurrent hepatitis C.","volume":"18","author":"Ross","year":"2004","journal-title":"Clin Transplant"},{"key":"R32-3-20250330","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1478-3231.2006.01261.x","article-title":"Impact of pegylated interferon 2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an openlabel series.","volume":"26","author":"Mukherjee","year":"2006","journal-title":"Liver Int"},{"key":"R33-3-20250330","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-6143.2006.01619.x","article-title":"Histological benefit of retreatment by pegylated interferon alfa2b and ribavirin in patients with recurrent hepatitis C virus infection posttransplantation.","volume":"7","author":"Bizollon","year":"2007","journal-title":"Am J Transplant"},{"key":"R34-3-20250330","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1097\/01.TP.0000129811.93072.1C","article-title":"Treatment of established recurrent hepatitis C in livertransplant recipients with pegylated interferonalfa2b and ribavirin therapy.","volume":"78","author":"Neff","year":"2004","journal-title":"Transplantation"},{"key":"R35-3-20250330","first-page":"24","article-title":"Increasing adherence to therapy for recurrent hepatitis C after liver transplantation by starting at lower drug doses and adding growth factors.","volume":"31","author":"Rahim","year":"2007","journal-title":"Practical Gastroenterol"},{"key":"R36-3-20250330","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/lt.21312","article-title":"Recurrent hepatitis C after liver transplantation: ontreatment prediction of response to peginterferonribavirin therapy.","volume":"14","author":"Hanouneh","year":"2008","journal-title":"Liver Transpl"},{"key":"R37-3-20250330","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jhep.2008.05.002","article-title":"Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin.","volume":"49","author":"Berenguer","year":"2008","journal-title":"J Hepatol"},{"key":"R38-3-20250330","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1111\/j.1600-6143.2005.00976.x","article-title":"Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.","volume":"5","author":"Bizollon","year":"2005","journal-title":"Am J Transplant"},{"key":"R40-3-20250330","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with peginterferon alfa2b plus ribavirin in patients with chronic hepatitis C.","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"key":"R41-3-20250330","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management, and treatment of hepatitis C.","volume":"39","author":"Strader","year":"2004","journal-title":"Hepatology"},{"key":"R42-3-20250330","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/lt.20189","article-title":"Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.","volume":"10","author":"Stravitz","year":"2004","journal-title":"Liver Transpl"},{"key":"R43-3-20250330","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.transproceed.2004.05.058","article-title":"De novo cryptogenic hepatitis after sustained eradication of hepatitis C following liver transplantation.","volume":"36","author":"Mukherjee","year":"2004","journal-title":"Transplant Proc"},{"key":"R44-3-20250330","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/lt.20706","article-title":"Pegylated interferoninduced immunemediated hepatitis postliver transplantation.","volume":"12","author":"Kontorinis","year":"2006","journal-title":"Liver Transpl"},{"key":"R45-3-20250330","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jhep.2006.12.017","article-title":"A randomized study on peginterferon alfa2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.","volume":"46","author":"Angelico","year":"2007","journal-title":"J Hepatol"},{"key":"R46-3-20250330","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1432-2277.1995.tb01709.x","article-title":"Ribavirin therapy for hepatitis C infection following liver transplantation.","volume":"8","author":"Gane","year":"1995","journal-title":"Transpl Int"},{"key":"R48-3-20250330","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/lt.20737","article-title":"Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.","volume":"12","author":"Berenguer","year":"2006","journal-title":"Liver Transpl"},{"issue":"suppl 20","key":"R52-3-20250330","first-page":"4","article-title":"Factors contributing to failure when treating patients with chronic hepatitis C virus infection.","volume":"3","author":"Shiffman","year":"2007","journal-title":"Gastroenterol Hepatol"},{"key":"R53-3-20250330","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0016-5085(99)70454-3","article-title":"European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.","volume":"117","author":"Feray","year":"1999","journal-title":"Gastroenterology"},{"key":"R54-3-20250330","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-2006-947292","article-title":"Extendeddonor criteria liver allografts.","volume":"26","author":"Alkofer","year":"2006","journal-title":"Semin Liver Dis"},{"key":"R55-3-20250330","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cld.2007.04.004","article-title":"Expanding donor options: marginal, living, and split donors.","volume":"11","author":"Foster","year":"2007","journal-title":"Clin Liver Dis"},{"key":"R56-3-20250330","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","article-title":"Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.","volume":"357","author":"McHutchison","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl","key":"R57-3-20250330","first-page":"244A","article-title":"Prophylactic peginterferon alfa2aribavirin vs no prophylaxis following orthotopic liver transplantation (OLT) for hepatitis C: 24week virologic and safety responses. abstract.","volume":"46","author":"Charlton","year":"2007","journal-title":"Hepatology"},{"key":"R58-3-20250330","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/lt.20889","article-title":"Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills?","volume":"12","author":"Davis","year":"2006","journal-title":"Liver Transpl"},{"key":"R59-3-20250330","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen.","volume":"329","author":"Samuel","year":"1993","journal-title":"N Engl J Med"},{"key":"R60-3-20250330","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-128-10-199805150-00003","article-title":"Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation.","volume":"128","author":"Feray","year":"1998","journal-title":"Ann Intern Med"},{"key":"R61-3-20250330","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/lt.20876","article-title":"Monoclonal antibody HCVAbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study.","volume":"12","author":"Schiano","year":"2006","journal-title":"Liver Transpl"},{"key":"R62-3-20250330","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/lt.20405","article-title":"A randomized, openlabel study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients.","volume":"11","author":"Davis","year":"2005","journal-title":"Liver Transpl"}],"container-title":["Liver Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flt.21694","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01445473-200902000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:07:04Z","timestamp":1743379624000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01445473-200902000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/lt.21694","relation":{},"ISSN":["1527-6465"],"issn-type":[{"type":"print","value":"1527-6465"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}